- Home
- Therapeutics
- Internal Medicine & Immunology
- Gastrointestinal
Gastrointestinal
91黑料 has experience in managing clinical studies in all major gastrointestinal indications
91黑料 has extensive experience in conducting gastrointestinal studies
We work across the entire drug development spectrum. Our experience ranges from the initial studies in Phase I through post-marketing efforts in Phase IV.
91黑料 Gastrointestinal experience in last five years:
-
114+
Studies -
28,400+
Patients involved -
10,000+
Sites
Broad disease experience
91黑料's Gastrointestinal team comprises dedicated drug development experts with significant experience conducting clinical trials for experimental therapeutics in the following diseases:
|
Diseases |
||
| Acid Reflux | Chronic Functional Constipation | Indigestion |
| Acute Gastric Pain | Crohn’s Disease | Idiopathic Gastroparesis |
| Acute Pancreatitis | Diarrhea | Inflammatory Bowel Disease |
| Bowel Prep | Diverticulitis | Irritable Bowel Syndrome |
| Celiac | Dyspepsia | Irritable Bowel Syndrome with Constipation |
| Chronic Constipation | Eosinophilic Esophagitis | Irritable Bowel Syndrome with Diarrhea |
| Colorectal Conditions | Esophagitis | Short Bowel Syndrome |
| Constipation | Gastroesophageal Reflux | Traveler's Diarrhea |
| Chronic Idiopathic Constipation | GERD | Ulcerative Colitis |
In this section
In this section
- Biosimilars
-
Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Endocrine & Metabolic Disorders
- Hepatology
- Infectious Diseases
- Internal Medicine & Immunology
-
Medical Device
-
Obesity
- Oncology
-
Pediatrics
- Rare & Orphan Diseases
- Vaccines
-
Women's Health
-
Therapeutics insights
- Biosimilars
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- Hepatology
-
Women's Health Insights
-
Oncology
- Pediatrics
-
Rare and orphan diseases
-
Pushing boundaries in idiopathic pulmonary fibrosis clinical research
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Pushing boundaries in idiopathic pulmonary fibrosis clinical research